We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer
Efficacy of niraparib in combination with an anti-PD-1 mAb surpasses historical efficacy benchmarks for PD-1 or PARP monotherapies in difficult-to-treat types of ovarian cancer, regardless of biomarker status Potential approach to reduce incidence of Grade 3 or 4 thrombocytopenia identified based
View HTML
Toggle Summary TESARO Announces Data Presentations at the 2018 American Association for Cancer Research Annual Meeting
WALTHAM, Mass. , March 14, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that data for ZEJULA, TSR-042 (anti-PD-1 antibody) and the company’s immuno-oncology portfolio will be presented at the 2018 American Association for Cancer
View HTML
Toggle Summary TESARO Announces Participation at Two Investor Conferences
WALTHAM, Mass. , March 01, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:       The Barclays Global Healthcare Conference at the Loews Hotel in
View HTML
Toggle Summary TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results
ZEJULA is the #1 PARP inhibitor for women with ovarian cancer in the U.S. 2017 ZEJULA ® net sales totaled $109 million during first nine months of commercial launch Focused clinical development program for niraparib in ovarian cancer is advancing in first-line and platinum-resistant settings
View HTML
Toggle Summary TESARO Announces Collaboration to Evaluate Combination of ZEJULA® (Niraparib) and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder Cancer
WALTHAM, Mass. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with Genentech, a member of the Roche Group , to evaluate the combination of the PD-L1 antibody
View HTML
Toggle Summary TESARO to Announce Fourth-Quarter 2017 Financial Results on February 27, 2018
WALTHAM, Mass. , Feb. 02, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce fourth-quarter 2017 financial results on Tuesday, February 27, 2018 , after the close of the U.S. financial markets. During the conference call and live audio webcast at 4:15 p.m.
View HTML
Toggle Summary TESARO Announces Updates to the U.S. Prescribing Information for VARUBI® (rolapitant) Injectable Emulsion
WALTHAM, Mass. , Jan. 12, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has updated the VARUBI® (rolapitant) injectable emulsion package insert in collaboration with the U.S. Food and Drug Administration ( FDA ).
View HTML
Toggle Summary TESARO Announces Availability of ZEJULA® (niraparib) for Women With Recurrent Ovarian Cancer in Germany
ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, without the need for BRCA testing and regardless of biomarker status ZEJULA is the only PARP inhibitor to offer once-daily, oral dosing that enables convenient administration for maintenance treatment
View HTML
Toggle Summary TESARO Announces Availability of VARUBI® (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United States
VARUBI injectable emulsion features ready-to-use, single-dose vial No saline, reconstitution or mixing is required to utilize VARUBI IV New formulation offers healthcare providers flexibility in their choice of antiemetic regimen Majority of NK-1 receptor antagonist doses are administered
View HTML
Toggle Summary TESARO Announces Participation in Two Investor Conferences
WALTHAM, Mass. , Nov. 22, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are: The Citi 2017 Global Healthcare Conference at the Lotte New York Palace in
View HTML